A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age

NCT05330975 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

3317

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus

Interventions

BIOLOGICAL: Placebo
BIOLOGICAL: mRNA-1345
BIOLOGICAL: Afluria® Quadrivalent
BIOLOGICAL: mRNA-1273.214

Sponsor

ModernaTX, Inc.